Funding for this research was provided by:
National Cancer Institute (CA160756, CA154887)
National Science Foundation (GRFP)
University of California, Cancer Research Coordinating Committee (CRN-17-427258)
University of California Senate Graduate Research Council (GRC-13)
Health Science Research Institute (HSRI)
Text and Data Mining valid from 2018-04-04
Received: 29 October 2017
Accepted: 21 February 2018
First Online: 4 April 2018
Ethics approval and consent to participate
: All experimental protocols were approved by the Institutional Review Boards at the University of California Merced and Irvine. The study was carried out as part of IRB UCM13–0025 of the University of California Merced and as part of dbGap ID 5094 for study accession phs000178.v9.p8 on somatic mutations in cancer and conducted in accordance with the Helsinki Declaration of 1975.
: There is no competing financial interest. FLM is co-Founder and Medical director of Cancer Prevention Pharmaceuticals with no direct implications on the conducted study on melanoma resistance.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.